Ningning Zhou

2.4k total citations · 1 hit paper
60 papers, 1.1k citations indexed

About

Ningning Zhou is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ningning Zhou has authored 60 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 21 papers in Molecular Biology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ningning Zhou's work include Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (17 papers) and RNA modifications and cancer (8 papers). Ningning Zhou is often cited by papers focused on Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (17 papers) and RNA modifications and cancer (8 papers). Ningning Zhou collaborates with scholars based in China, Hong Kong and Macao. Ningning Zhou's co-authors include Yan Huang, Yuxiang Ma, Hongyun Zhao, Yunpeng Yang, Shaodong Hong, Yuanyuan Zhao, Likun Chen, Wenfeng Fang, Li Zhang and Xue Hou and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ningning Zhou

56 papers receiving 1.1k citations

Hit Papers

Camrelizumab (SHR-1210) alone or in combination with gemc... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
    2018 326 citations Wenfeng Fang, Yunpeng Yang et al. The Lancet Oncology profile →

Peers

Ningning Zhou
Fuxiang Zhou China
Farhat Ben Ayed Tunisia
Huimin Tian China
Beverly R. Wuertz United States
Adam Maciejczyk Poland
Bin Qiao China
CS Potten United Kingdom
Sophie Espenel France
Min Kang China
Huihua Xiong China
Fuxiang Zhou China
Ningning Zhou
Citations per year, relative to Ningning Zhou Ningning Zhou (= 1×) peers Fuxiang Zhou

Countries citing papers authored by Ningning Zhou

Since Specialization
Citations

This map shows the geographic impact of Ningning Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ningning Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ningning Zhou more than expected).

Fields of papers citing papers by Ningning Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ningning Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ningning Zhou. The network helps show where Ningning Zhou may publish in the future.

Co-authorship network of co-authors of Ningning Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Ningning Zhou. A scholar is included among the top collaborators of Ningning Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ningning Zhou. Ningning Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Huang, Yan, Yunpeng Yang, Yuanyuan Zhao, et al.. (2024). QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study. Signal Transduction and Targeted Therapy. 9(1). 23–23. 10 indexed citations
3.
4.
Zhang, Jiexia, Ningning Zhou, Huojin Deng, et al.. (2023). Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer. Lung Cancer. 178. 11–19. 8 indexed citations
5.
Yang, Xia, Weizhong Chen, Fang Wang, et al.. (2023). m6A‐Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis. Advanced Science. 10(20). e2206744–e2206744. 31 indexed citations
6.
7.
Su, Zhipeng, Ningning Zhou, Fugen Shangguan, et al.. (2021). Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling. Cell Death and Disease. 12(3). 251–251. 24 indexed citations
8.
Cheng, Ying, Lin Wu, Yongping Huang, et al.. (2021). P48.08 Phase IV Clinical Study on the Safety and Efficacy of Lobaplatin-Based Regimen With Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S502–S503. 2 indexed citations
9.
Qi, Jianjun, Ningning Zhou, Liyi Li, et al.. (2020). Ciclopirox activates PERK-dependent endoplasmic reticulum stressto drive cell death in colorectal cancer. Cell Death and Disease. 11(7). 582–582. 37 indexed citations
10.
Cao, Zhili, et al.. (2020). Efficacy of on-pump coronary artery bypass grafting and stent implantation combined with surgery on lung cancer.. PubMed. 24(6). 2253–2259. 1 indexed citations
11.
Zhang, Jiexia, Ningning Zhou, Anqi Lin, et al.. (2020). ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunology Immunotherapy. 70(1). 137–151. 67 indexed citations
12.
Wang, Ruiqi, Xiaoran Long, Chunlei Ge, et al.. (2020). Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China. Journal of Translational Medicine. 18(1). 320–320. 7 indexed citations
13.
Li, Zhi‐Ling, Hai‐Liang Zhang, Yun Huang, et al.. (2020). Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nature Communications. 11(1). 3806–3806. 136 indexed citations
14.
Zhang, Rusi, Ling Cai, Gongming Wang, et al.. (2020). Resection of Early-Stage Second Primary Non-small Cell Lung Cancer After Small Cell Lung Cancer: A Population-Based Study. Frontiers in Oncology. 9. 1552–1552. 7 indexed citations
15.
Cai, Ling, Weidong Wang, Fang Wang, et al.. (2019). A comparison of MASS-PCR and ARMS-PCR for the detection of lung cancer gene mutation. Translational Cancer Research. 8(7). 2564–2569. 1 indexed citations
16.
Fang, Wenfeng, Yunpeng Yang, Yuxiang Ma, et al.. (2018). Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. The Lancet Oncology. 19(10). 1338–1350. 326 indexed citations breakdown →
17.
Zhou, Ting, Xiaobo He, Wen‐Feng Fang, et al.. (2016). Pretreatment Albumin/Globulin Ratio Predicts the Prognosis for Small-Cell Lung Cancer. Medicine. 95(12). e3097–e3097. 47 indexed citations
18.
Qin, Tao, Ningning Zhou, Xiao-Xiao Dinglin, et al.. (2016). Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase. OncoTargets and Therapy. 9. 1095–1095. 6 indexed citations
19.
Ding, Lingyu, Kejun Liu, Qi Chen, et al.. (2014). The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC). Tumor Biology. 36(4). 2491–2499. 7 indexed citations
20.
Zhou, Ningning, et al.. (1991). Identification of Alien Chromatin and Ribosomal DNA in Wheat by in Situ Hybridization. Zhiwu xuebao. 33(6). 437–442. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fuxiang Zhou Breakdown of academic impact, for papers by Farhat Ben Ayed Breakdown of academic impact, for papers by Huimin Tian Breakdown of academic impact, for papers by Beverly R. Wuertz Breakdown of academic impact, for papers by Adam Maciejczyk Breakdown of academic impact, for papers by Bin Qiao Breakdown of academic impact, for papers by CS Potten Breakdown of academic impact, for papers by Sophie Espenel Breakdown of academic impact, for papers by Min Kang Breakdown of academic impact, for papers by Huihua Xiong
Rankless by CCL
2026